▲ +31.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Calliditas Therapeutics AB (publ) in the last 3 months. The average price target is $38.00, with a high forecast of $44.00 and a low forecast of $28.00. The average price target represents a 31.67% upside from the last price of $28.86.
The current consensus among 4 investment analysts is to buy stock in Calliditas Therapeutics AB (publ).
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.